Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers or acquirers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”). Pacira is a pharmaceutical company.

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: Rosen Law Firm is Investigating the Allegations that Pacira BioSciences, Inc. (NASDAQ: PCRX) Misled Investors Regarding its Business Operations.

According to the complaint, statements made during the Class Period were false and/or misleading because defendants created the false impression that Pacira had sufficient patent protections on Exparel and, as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue. In truth, Pacira’s optimistic claims pertaining to its patent protections on Exparel were fragile at best. In fact, Pacira knew that the ‘495 patent was not as protective as defendants publicly touted because on June 6, 2023 the New Jersey District Court issued a ruling in eVenus’s favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel. Yet defendants continued to make public statements affirming their belief in the ‘495 patent and the protection it applied for Exparel. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against Pacira BioSciences, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by March 14, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.